-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Acorda Therapeutics (NASDAQ:ACOR) Receives New Coverage From Analysts at StockNews.com
Acorda Therapeutics (NASDAQ:ACOR) Receives New Coverage From Analysts at StockNews.com
StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research note released on Sunday. The brokerage issued a hold rating on the biopharmaceutical company's stock.
Acorda Therapeutics Price Performance
ACOR stock opened at $0.31 on Friday. Acorda Therapeutics has a 1 year low of $0.28 and a 1 year high of $4.99. The company has a market cap of $7.53 million, a P/E ratio of -0.03 and a beta of 0.45. The firm has a 50-day moving average of $0.43 and a 200 day moving average of $0.83. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.86 and a quick ratio of 1.49.
Get Acorda Therapeutics alerts:Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($2.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($2.42). Acorda Therapeutics had a negative return on equity of 90.29% and a negative net margin of 98.25%. The company had revenue of $31.05 million during the quarter.
Hedge Funds Weigh In On Acorda Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in ACOR. Renaissance Technologies LLC increased its stake in shares of Acorda Therapeutics by 27.4% during the second quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock valued at $420,000 after purchasing an additional 194,100 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Acorda Therapeutics during the second quarter valued at approximately $68,000. Millennium Management LLC increased its stake in shares of Acorda Therapeutics by 661.2% during the second quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock valued at $145,000 after purchasing an additional 270,588 shares in the last quarter. Finally, Prudential Financial Inc. bought a new position in shares of Acorda Therapeutics during the second quarter valued at approximately $28,000. Institutional investors own 50.24% of the company's stock.About Acorda Therapeutics
(Get Rating)
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Further Reading
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research note released on Sunday. The brokerage issued a hold rating on the biopharmaceutical company's stock.
斯托克新聞網在週日發佈的一份研究報告中對阿科達治療公司(納斯達克：ACOR-GET評級)的股票進行了報道。該經紀公司對這家生物製藥公司的股票發佈了持有評級。
Acorda Therapeutics Price Performance
Acorda治療公司的性價比
ACOR stock opened at $0.31 on Friday. Acorda Therapeutics has a 1 year low of $0.28 and a 1 year high of $4.99. The company has a market cap of $7.53 million, a P/E ratio of -0.03 and a beta of 0.45. The firm has a 50-day moving average of $0.43 and a 200 day moving average of $0.83. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.86 and a quick ratio of 1.49.
雅高股價上週五開盤報0.31美元。Acorda Treeutics的一年低點為0.28美元，一年高位為4.99美元。該公司市值為753萬美元，市盈率為-0.03，貝塔係數為0.45。該公司的50日移動均線切入位在0.43美元，200日移動均線切入位在0.83美元。該公司的債務權益比為2.10，流動比率為1.86，速動比率為1.49。
Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($2.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($2.42). Acorda Therapeutics had a negative return on equity of 90.29% and a negative net margin of 98.25%. The company had revenue of $31.05 million during the quarter.
阿科達治療公司(納斯達克：ACOR-GET評級)最近一次發佈季度收益報告是在8月4日星期四。這家生物製藥公司公佈的季度每股收益(EPS)為2.78美元，低於分析師普遍預期的0.36美元和2.42美元。阿科達治療公司的淨資產回報率為負90.29%，淨利潤率為負98.25%。該公司本季度的收入為3105萬美元。
Hedge Funds Weigh In On Acorda Therapeutics
對衝基金入股Acorda Treeutics
About Acorda Therapeutics
關於阿科達治療公司
(Get Rating)
(獲取評級)
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Acorda治療公司是一家生物製藥公司，在美國開發和銷售神經疾病的治療方法。該公司在歐洲營銷Ampyra(達法普利定)，一種改善多發性硬化症(MS)患者行走能力的口服藥物；以及Inbrija，用於治療帕金森病的間歇期。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 免費獲取StockNews.com關於Acorda治療公司(ACOR)的研究報告
- 對塔吉特來説，最糟糕的時期可能已經過去，但這隻股票買起來安全嗎？
- 這些液態天然氣股票準備好上行了嗎？
- 內部人士正在買入的兩隻有趣的股票
- 諾華在避險市場中仍是一隻冒險的股票
- 連續60年提高股息的3只防御性股票
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Acorda治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Acorda Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧